Kurzfassung

An open-label, randomized, phase III study of Inotuzumab Ozogamicin administered in combination with Rituximab compared to defined investigators choice therapy in subjects with relapsed or refractory CD22-positive aggressive Non-Hodgkin-Lymphoma who are not candidates for intensive high dose chemotherapy